Selective delivery of oxaliplatin to tumor tissue by nanocarrier system enhances overall therapeutic efficacy of the encapsulated oxaliplatin

Biological and Pharmaceutical Bulletin

Volumn 37, Issue 2, 2014, Pages 206-211

  Lila, Amr Selim Abu ^a,b   Kiwada, Hiroshi ^a   Ishida, Tatsuhiro ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b Zagazig University   (Egypt)

Author keywords

(l OHP); Carbon nanotube; Enhanced permeability and retention (epr) effect; Liposome; Polymeric nanoparticle

Indexed keywords

CARBON NANOTUBE; CATION; CHITOSAN; COPOLYMER; EUDRAGIT; HYDROXYPROPYLCELLULOSE; LIPOSOME; MACROGOL; MACROGOL 600; MICROSPHERE; MULTI WALLED NANOTUBE; NANOCARRIER; NANOSPHERE; OXALIPLATIN; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; POLYACRYLAMIDE; POLYACRYLIC ACID; POLYGLUTAMIC ACID; POLYSTYRENE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BIOACCUMULATION; COLON TUMOR; COLORECTAL CANCER; CONTROLLED RELEASE FORMULATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG STRUCTURE; ESOPHAGUS CANCER; HUMAN; HYDROGEL; LYMPH NODE METASTASIS; MALIGNANT NEOPLASTIC DISEASE; MICELLE; NANOENCAPSULATION; NANOPHARMACEUTICS; NONHUMAN; PHYSICAL CHEMISTRY; REVIEW; STOMACH CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG CARRIERS; HUMANS; NANOPARTICLES; ORGANOPLATINUM COMPOUNDS;

EID: 84893510536     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00540     Document Type: Review

References (65)

1. Hardman WE, Moyer MP, Cameron IL. Efficacy of treatment of colon, lung and breast human carcinoma xenografts with: doxorubicin, cisplatin, irinotecan or topotecan. Anticancer Res., 19 (3B), 2269-2274 (1999).
2. Ridwelski K, Gebauer T, Fahlke J, Kroning H, Kettner E, Meyer F, Eichelmann K, Lippert H. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann. Oncol., 12, 47-51 (2001).
3. Gillet JP, Gottesman MM. Mechanisms of multidrug resistance in cancer. Methods Mol. Biol., 596, 47-76 (2010).
4. Torchilin VP. Drug targeting. Eur. J. Pharm. Sci., 11 (Suppl. 2), S81-S91 (2000).
5. Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Health Technol. Assess., 12, iii-ix, xi-162 (2008).
6. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol., 18, 2938-2947 (2000).
7. Zeuli M, Di Costanzo E, Sdrobolini A, Gasperoni S, Paoloni FP, Carpi A, Moscetti L, Cherubini R, Cognetti FGruppo Oncologico Italiano per la Ricerca Clinica (GOIRC)Gruppo Oncologico Laziale (GOL). Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study. Ann. Oncol., 12, 1737-1741 (2001).
8. Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res., 53, 5970-5976 (1993).
9. Abu-Lila A, Suzuki T, Doi Y, Ishida T, Kiwada H. Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model. J. Control. Release, 134, 18-25 (2009).
10. Sahay G, Kim JO, Kabanov AV, Bronich TK. The exploitation of differential endocytic pathways in normal and tumor cells in the selective targeting of nanoparticulate chemotherapeutic agents. Biomaterials, 31, 923-933 (2010).
11. Wang L, Zeng R, Li C, Qiao R. Self-assembled polypeptide-block- poly(vinylpyrrolidone) as prospective drug-delivery systems. Colloids Surf. B Biointerfaces, 74, 284-292 (2009).
12. Noguchi Y, Wu J, Duncan R, Strohalm J, Ulbrich K, Akaike T, Maeda H. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res., 89, 307-314 (1998).
13. Bussemer T, Dashevsky A, Bodmeier R. A pulsatile drug delivery system based on rupturable coated hard gelatin capsules. J. Control. Release, 93, 331-339 (2003).
14. Hrubý M, Konak C, Ulbrich K. Polymeric micellar pH-sensitive drug delivery system for doxorubicin. J. Control. Release, 103, 137-148 (2005).
15. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science, 263, 1600-1603 (1994).
16. Jain A, Jain SK, Ganesh N, Barve J, Beg AM. Design and development of ligand-appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer. Nanomedicine, 6, 179-190 (2010).
17. Kwon GS. Polymeric micelles for delivery of poorly water-soluble compounds. Crit. Rev. Ther. Drug Carrier Syst., 20, 357-403 (2003).
18. Jeong YI, Na HS, Cho KO, Lee HC, Nah JW, Cho CS. Antitumor activity of adriamycin-incorporated polymeric micelles of poly(gamma-benzyl L-glutamate)/poly(ethylene oxide). Int. J. Pharm., 365, 150-156 (2009).
19. Jeong YI, Nah JW, Lee HC, Kim SH, Cho CS. Adriamycin release from flower-type polymeric micelle based on star-block copolymer composed of poly(gamma-benzyl L-glutamate) as the hydrophobic part and poly(ethylene oxide) as the hydrophilic part. Int. J. Pharm., 188, 49-58 (1999).
20. Yokoyama M, Miyauchi M, Yamada N, Okano T, Sakurai Y, Kataoka K, Inoue S. Characterization and anticancer activity of the micelle-forming polymeric anticancer drug adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. Cancer Res., 50, 1693-1700 (1990).
21. Croy SR, Kwon GS. Polymeric micelles for drug delivery. Curr. Pharm. Des., 12, 4669-4684 (2006).
22. Kwon GS, Naito M, Yokoyama M, Okano T, Sakurai Y, Kataoka K. Physical entrapment of adriamycin in AB block copolymer micelles. Pharm. Res., 12, 192-195 (1995).
23. Kim D, Lee ES, Park K, Kwon IC, Bae YH. Doxorubicin loaded pH-sensitive micelle: antitumoral efficacy against ovarian A2780/DOXR tumor. Pharm. Res., 25, 2074-2082 (2008).
24. Cabral H, Nishiyama N, Kataoka K. Optimization of (1,2- diaminocyclohexane)platinum(II)-loaded polymeric micelles directed to improved tumor targeting and enhanced antitumor activity. J. Control. Release, 121, 146-155 (2007).
25. Rafi M, Cabral H, Kano MR, Mi P, Iwata C, Yashiro M, Hirakawa K, Miyazono K, Nishiyama N, Kataoka K. Polymeric micelles incorporating (1,2-diaminocyclohexane)platinum(II) suppress the growth of orthotopic scirrhous gastric tumors and their lymph node metastasis. J. Control. Release, 159, 189-196 (2012).
26. Wang K, Liu L, Zhang T, Zhu YL, Qiu F, Wu XG, Wang XL, Hu FQ, Huang J. Oxaliplatin-incorporated micelles eliminate both cancer stem-like and bulk cell populations in colorectal cancer. Int. J. Nanomedicine, 6, 3207-3218 (2011).
27. Chen Y, Ding D, Mao Z, He Y, Hu Y, Wu W, Jiang X. Synthesis of hydroxypropylcellulose-poly(acrylic acid) particles with semi-interpenetrating polymer network structure. Biomacromolecules, 9, 2609-2614 (2008).
28. Alexakis T, Boadi DK, Quong D, Groboillot A, O'Neill I, Poncelet D, Neufeld RJ. Microencapsulation of DNA within alginate microspheres and crosslinked chitosan membranes for in vivo application. Appl. Biochem. Biotechnol., 50, 93-106 (1995).
29. Alakhov VY, Kabanov AV. Block copolymeric biotransport carriers as versatile vehicles for drug delivery. Expert Opin. Investig. Drugs, 7, 1453-1473 (1998).
30. Li JQ, Wang SL, Xu F, Liu ZY, Li R. Therapeutic effectiveness of slow-release PLGA-oxaliplatin microsphere on human colorectal tumor-bearing mice. Anticancer Drugs, 21, 600-608 (2010).
31. Iijima S, Ajayan PM, Ichihashi T. Growth model for carbon nanotubes. Phys. Rev. Lett., 69, 3100-3103 (1992).
32. Bhirde AA, Patel V, Gavard J, Zhang G, Sousa AA, Masedunskas A, Leapman RD, Weigert R, Gutkind JS, Rusling JF. Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery. ACS Nano, 3, 307-316 (2009).
33. Liu Z, Cai W, He L, Nakayama N, Chen K, Sun X, Chen X, Dai H. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat. Nanotechnol., 2, 47-52 (2007).
34. Shi Kam NW, Jessop TC, Wender PA, Dai H. Nanotube molecular transporters: Internalization of carbon nanotube-protein conjugates into mammalian cells. J. Am. Chem. Soc., 126, 6850-6851 (2004).
35. Kam NW, Liu Z, Dai H. Functionalization of carbon nanotubes via cleavable disulfide bonds for efficient intracellular delivery of siRNA and potent gene silencing. J. Am. Chem. Soc., 127, 12492-12493 (2005).
36. Wu L, Man C, Wang H, Lu X, Ma Q, Cai Y, Ma W. PEGylated multi-walled carbon nanotubes for encapsulation and sustained release of oxaliplatin. Pharm. Res., 30, 412-423 (2013).
37. Chang HI, Yeh MK. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int. J. Nanomedicine, 7, 49-60 (2012).
38. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov., 4, 145-160 (2005).
39. Ranson M, Howell A, Cheeseman S, Margison J. Liposomal drug delivery. Cancer Treat. Rev., 22, 365-379 (1996).
40. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev., 65, 36-48 (2013).
41. Mayer LD, Bally MB, Cullis PR. Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim. Biophys. Acta, 857, 123-126 (1986).
42. Mayer LD, Tai LC, Ko DS, Masin D, Ginsberg RS, Cullis PR, Bally MB. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res., 49, 5922-5930 (1989).
43. Fenske DB, Cullis PR. Entrapment of small molecules and nucleic acid-based drugs in liposomes. Methods Enzymol., 391, 7-40 (2005).
44. Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. U.S.A., 85, 6949-6953 (1988).
45. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett., 268, 235-237 (1990).
46. Allen TM, Chonn A. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett., 223, 42-46 (1987).
47. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res., 46, 6387-6392 (1986).
48. Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur. J. Pharm. Biopharm., 71, 409-419 (2009).
49. Andresen TL, Jensen SS, Jorgensen K. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog. Lipid Res., 44, 68-97 (2005).
50. Metselaar JM, Mastrobattista E, Storm G. Liposomes for intravenous drug targeting: design and applications. Mini Rev. Med. Chem., 2, 319-329 (2002).
51. Yang C, Liu HZ, Lu WD, Fu ZX. PEG-liposomal oxaliplatin potentialization of antitumor efficiency in a nude mouse tumor-xenograft model of colorectal carcinoma. Oncol. Rep., 25, 1621-1628 (2011).
52. Spragg DD, Alford DR, Greferath R, Larsen CE, Lee KD, Gurtner GC, Cybulsky MI, Tosi PF, Nicolau C, Gimbrone MA Jr. Immunotargeting of liposomes to activated vascular endothelial cells: a strategy for site-selective delivery in the cardiovascular system. Proc. Natl. Acad. Sci. U.S.A., 94, 8795-8800 (1997).
53. Voinea M, Manduteanu I, Dragomir E, Capraru M, Simionescu M. Immunoliposomes directed toward VCAM-1 interact specifically with activated endothelial cells-a potential tool for specific drug delivery. Pharm. Res., 22, 1906-1917 (2005).
54. Völkel T, Holig P, Merdan T, Muller R, Kontermann RE. Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed against human endoglin (CD105). Biochim. Biophys. Acta, 1663, 158-166 (2004).
55. Bloemen PG, Henricks PA, van Bloois L, van den Tweel MC, Bloem AC, Nijkamp FP, Crommelin DJ, Storm G. Adhesion molecules: a new target for immunoliposome-mediated drug delivery. FEBS Lett., 357, 140-144 (1995).
56. Suzuki R, Takizawa T, Kuwata Y, Mutoh M, Ishiguro N, Utoguchi N, Shinohara A, Eriguchi M, Yanagie H, Maruyama K. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome. Int. J. Pharm., 346, 143-150 (2008).
57. Wehland M, Bauer J, Magnusson NE, Infanger M, Grimm D. Biomarkers for anti-angiogenic therapy in cancer. Int. J. Mol. Sci., 14, 9338-9364 (2013).
58. Ledzewicz U, Marriott J, Maurer H, Schattler H. Realizable protocols for optimal administration of drugs in mathematical models for anti-angiogenic treatment. Math. Med. Biol., 27, 157-179 (2010).
59. Tagami T, Suzuki T, Matsunaga M, Nakamura K, Moriyoshi N, Ishida T, Kiwada H. Anti-angiogenic therapy via cationic liposome-mediated systemic siRNA delivery. Int. J. Pharm., 422, 280-289 (2012).
60. Abu Lila AS, Ishida T, Kiwada H. Targeting anticancer drugs to tumor vasculature using cationic liposomes. Pharm. Res., 27, 1171-1183 (2010).
61. Abu Lila AS, Kizuki S, Doi Y, Suzuki T, Ishida T, Kiwada H. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model. J. Control. Release, 137, 8-14 (2009).
62. Abu Lila AS, Doi Y, Nakamura K, Ishida T, Kiwada H. Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor. J. Control. Release, 142, 167-173 (2010).
63. Kalra AV, Campbell RB. Development of 5-FU and doxorubicin-loaded cationic liposomes against human pancreatic cancer: Implications for tumor vascular targeting. Pharm. Res., 23, 2809-2817 (2006).
64. Arnould S, Guichard S, Hennebelle I, Cassar G, Bugat R, Canal P. Contribution of apoptosis in the cytotoxicity of the oxaliplatin-irinotecan combination in the HT29 human colon adenocarcinoma cell line. Biochem. Pharmacol., 64, 1215-1226 (2002).
65. Eriguchi M, Nonaka Y, Yanagie H, Yoshizaki I, Takeda Y, Sekiguchi M. A molecular biological study of anti-tumor mechanisms of an anti-cancer agent oxaliplatin against established human gastric cancer cell lines. Biomed. Pharmacother., 57, 412-415 (2003).